Nanoparticle delivery systems engineered to target lesion sites stand to impact not only AD but also diverse neurodegenerative disease conditions originating from the abnormality of protein aggregation, such as amyloid plaques, hyperphosphorylated tau, and other associated pathogenic factors in the brain. Here, MAPT is linked to Alzheimer disease.